GPC Biotech Meeting and Conference Call on Third Quarter 2007 Results
Scheduled for November 8th
Martinsried/Munich (Germany) and Princeton, N.J., November 2, 2007 -
GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ:
GPCB) today announced that the Company will hold an analyst and press
meeting in Frankfurt, Germany to discuss financial results for the
third quarter and first nine months of 2007. The results will be
published on November 8th in advance of the call.
The meeting, which will be conducted in English, will be held
Thursday, November 8, 2007 at 3 PM CET/9 AM ET in Frankfurt.
The meeting will also be accessible via telephone or webcast. The
live webcast, including synchronized slides, will be available on the
GPC Biotech Web site at www.gpc-biotech.com. A replay will be
available via the Web site following the live event.
Dial-in numbers for the meeting are as follows:
Participants from Europe: 0049-(0)89-9982-99913 or
0044-(0)20-7806-1961
Participants from the U.S.: 1-718-354-1391
Please dial in 10 minutes before the beginning of the meeting.
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused
on discovering, developing and commercializing new anticancer drugs.
GPC Biotech's lead product candidate is satraplatin, an oral platinum
compound. The Company has various anti-cancer programs in research
and development that leverage its expertise in kinase inhibitors. GPC
Biotech AG is headquartered in Martinsried/Munich (Germany) and has a
wholly owned U.S. subsidiary headquartered in Princeton, New Jersey.
For additional information, please visit GPC Biotech's Web site at
www.gpc-biotech.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC Biotech
AG. Such statements are based on current expectations and are
subject to risks and uncertainties, many of which are beyond our
control, that could cause future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and
we caution investors not to place undue reliance on the
forward-looking statements contained in this press release We direct
you to GPC Biotech's Annual Report on Form 20-F for the fiscal year
ended December 31, 2006 and other reports filed with the U.S.
Securities and Exchange Commission for additional details on the
important factors that may affect the future results, performance and
achievements of GPC Biotech. Forward-looking statements speak only as
of the date on which they are made and GPC Biotech undertakes no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
Contacts:
GPC Biotech AG
Martin Braendle
Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
usinvestors@gpc-biotech.com
--- End of Message ---
GPC Biotech AG
Fraunhoferstr. 20 Martinsried
WKN: 585150; ISIN:
DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX,
TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Geregelter Markt in Frankfurter Wertpapierbörse;
